enVVeno Medical Corporation (NVNO) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Devices secteur d'activité. Le siège social de l'entreprise est situé à Irvine, CA, United States. Le PDG actuel est Robert A. Berman.
NVNO a date d'introduction en bourse 2018-05-31, 37 employés à temps plein, cotée sur le NASDAQ Capital Marke, une capitalisation boursière de $186.15K.
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
